Calvin Yeang Selected Research

1-penicillamyl-Leu(2)- oxytocin

1/2020	ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis.
1/2019	Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids.
12/2018	Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels: Secondary Analysis of a Randomized Clinical Trial.
1/2018	Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice.
5/2016	Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a).
9/2015	Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Calvin Yeang Research Topics

Disease

11	Aortic Valve Stenosis (Aortic Stenosis) 01/2022 - 09/2015
8	Atherosclerosis 01/2022 - 09/2007
6	Inflammation (Inflammations) 01/2022 - 03/2011
4	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 02/2016
3	Thrombosis (Thrombus) 01/2022 - 08/2016
2	Death (Near-Death Experience) 01/2020 - 09/2015
2	Atherosclerotic Plaque (Atheroma) 01/2018 - 02/2016
1	Coronary Disease (Coronary Heart Disease) 12/2020
1	Stroke (Strokes) 12/2020
1	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 12/2020
1	Reperfusion Injury 01/2019
1	Myocardial Infarction 01/2019
1	Infarction (Infarctions) 01/2019
1	Arteritis 08/2016
1	Edema (Dropsy) 03/2011
1	Lung Injury 03/2011

Drug/Important Bio-Agent (IBA)

16	Lipoprotein(a)IBA 01/2022 - 09/2015
8	Phospholipids (Phosphatides)FDA LinkGeneric 01/2019 - 10/2010
6	CholesterolIBA 12/2020 - 09/2007
6	1-penicillamyl-Leu(2)- oxytocinIBA 01/2020 - 09/2015
4	Apolipoproteins B (ApoB)IBA 01/2020 - 09/2015
3	Lipoproteins (Lipoprotein)IBA 01/2022 - 09/2007
3	oxidized low density lipoproteinIBA 12/2020 - 01/2020
3	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2020 - 01/2016
3	Apolipoproteins AIBA 01/2020 - 02/2016
2	LDL CholesterolIBA 01/2022 - 12/2020
2	Apolipoprotein B-100 (Apo B 100)IBA 12/2020 - 05/2016
2	LDL Lipoproteins (beta Lipoproteins)IBA 01/2020 - 02/2016
2	Single-Chain AntibodiesIBA 01/2019 - 01/2018
2	Apoprotein(a) (Apolipoprotein (a))IBA 12/2018 - 02/2016
2	Rosuvastatin Calcium (Crestor)FDA Link 12/2018 - 09/2015
2	EpitopesIBA 01/2018 - 11/2014
1	celastrolIBA 01/2020
1	Apolipoprotein C-IIIIBA 01/2020
1	Phosphatidylcholines (Phosphatidylcholine)IBA 01/2019
1	ApolipoproteinsIBA 12/2018
1	Apolipoproteins E (ApoE)IBA 01/2018
1	Malondialdehyde (Propanedial)IBA 01/2018
1	AcetaldehydeIBA 01/2018
1	Serum Amyloid A Protein (Serum Amyloid A)IBA 01/2018
1	N 30IBA 08/2016
1	A 7 (A-7)IBA 08/2016
1	Biological ProductsIBA 05/2016
1	LDL Receptors (LDL Receptor)IBA 02/2016
1	AntigensIBA 11/2014
1	LipopolysaccharidesIBA 03/2011
1	CytokinesIBA 03/2011
1	phosphatidylcholine-ceramide phosphocholine transferaseIBA 03/2011
1	Phosphotransferases (Kinase)IBA 03/2011
1	LipidsIBA 10/2010
1	Phospholipid Transfer ProteinsIBA 09/2007

Therapy/Procedure

5	Therapeutics 12/2018 - 06/2011
1	Transcatheter Aortic Valve Replacement 04/2019